AlzProtect’s Candidate Therapy AZP2006 Well-tolerated in Healthy Volunteers, Phase 1 Trial Shows

AlzProtect’s Candidate Therapy AZP2006 Well-tolerated in Healthy Volunteers, Phase 1 Trial Shows
A Phase 1 clinical trial in healthy volunteers for investigational therapy AZP2006 — an oral medicine that is meant to clear accumulations of toxic proteins in Alzheimer’s disease and progressive supranuclear palsy — has shown positive results, says the therapy's developer, AlzProtect. Progressive supranuclear palsy (PSP) is a rare, progressive disease that arises due to loss of brain cells as a result of accumulations of abnormal tau protein aggregates. The study, launched in 2018, investigated the effect of food intake on the pha
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *